Genetic polymorphisms in matrix metalloproteinases (MMPs) and tissue inhibitors of MPs (TIMPs), and bladder cancer susceptibility

BJU International

Volumn 112, Issue 8, 2013, Pages 1207-1214

  Wieczorek, Edyta ^a   Reszka, Edyta ^a   Jablonowski, Zbigniew ^b   Jablonska, Ewa ^a   Beata Krol, Magdalena ^a   Grzegorczyk, Adam ^b   Gromadzinska, Jolanta ^a   Sosnowski, Marek ^b   Wasowicz, Wojciech ^a  

^a NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

bladder cancer; case control study; genetic polymorphism; MMP; susceptibility; TIMP

Indexed keywords

MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MMP1 GENE; MMP12 GENE; MMP2 GENE; MMP9 GENE; ONCOGENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SMOKING; TIMP1 GENE; TIMP3 GENE;

BLADDER CANCER; CASE-CONTROL STUDY; GENETIC POLYMORPHISM; MMP; SUSCEPTIBILITY; TIMP;

AGED; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; ODDS RATIO; POLAND; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; SMOKING; TISSUE INHIBITOR OF METALLOPROTEINASE-1; URINARY BLADDER NEOPLASMS;

EID: 84887318632     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12230     Document Type: Article

References (61)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249
2. Didkowska J, Wojciechowska U, Zatonski W,. Cancer incidence-tables and figures. In, Zatonski W, ed., Cancer in Poland in 2009, Chapt 5. Warszawa: Maria Skłodowska-Curie Institute of Oncology, 2011: 51-80
3. Parkin DM,. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 2008; 218: 12-20
4. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP,. Biology and management of bladder cancer. N Engl J Med 1990; 322: 1129-1138
5. Soloway MS, Sofer M, Vaidya A,. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002; 167: 1573-1583
6. Gross J, Lapiere CM,. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci USA 1962; 48: 1014-1022
7. Overall CM,. Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol Biotechnol 2002; 22: 51-86
8. Nabeshima K, Inoue T, Shimao Y, Sameshima T,. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 2002; 52: 255-264
9. Joos L, He JQ, Shepherdson MB, et al. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet 2002; 11: 569-576
10. Back M, Ketelhuth DF, Agewall S,. Matrix Metalloproteinases in atherothrombosis. Prog Cardiovasc Dis 2010; 52: 410-428
11. Lambert E, Dasse E, Haye B, Petitfrere E,. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004; 49: 187-198
12. Sternlicht MD, Werb Z,. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516
13. Beranek M, Kankova K, Muzik J,. Identification of novel common polymorphisms in the promoter region of the TIMP-3 gene in Czech population. Mol Cell Probes 2000; 14: 265-268
14. Peterson NB, Beeghly-Fadiel A, Gao YT, et al. Polymorphisms in tissue inhibitors of metalloproteinases-2 and-3 and breast cancer susceptibility and survival. Int J Cancer 2009; 125: 844-850
15. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP,. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111-122
16. Butler GS, Apte SS, Willenbrock F, Murphy G,. Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B. Regulation by polyanions. J Biol Chem 1999; 274: 10846-10851
17. Fujimoto N, Ward RV, Shinya T, Iwata K, Yamashita K, Hayakawa T,. Interaction between tissue inhibitor of metalloproteinases-2 and progelatinase A: immunoreactivity analyses. Biochem J 1996; 313: 827-833
18. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI,. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995; 270: 5331-5338
19. Kahari VM, Saarialho-Kere U,. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999; 31: 34-45
20. Ponton A, Coulombe B, Skup D,. Decreased expression of tissue inhibitor of metalloproteinases in metastatic tumor cells leading to increased levels of collagenase activity. Cancer Res 1991; 51: 2138-2143
21. Hojilla CV, Mohammed FF, Khokha R,. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2003; 89: 1817-1821
22. Cruz-Munoz W, Khokha R,. The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci 2008; 45: 291-338
23. Li L, Zhang S, Lin H, Lin JY,. Relationship of expression unbalance of matrix metalloproteinase and tissue inhibitor of metalloproteinase to invasiveness and metastasis in gastric carcinomas. Ai Zheng 2002; 21: 305-310
24. Dos Reis ST, Pontes J Jr, Villanova FE, et al. Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer. J Urol 2009; 181: 2320-2325
25. Wu CY, Wu MS, Chen YJ, et al. Clinicopathologicalsignificance of MMP-2 and TIMP-2 genotypes in gastric cancer. Eur J Cancer 2007; 43: 799-808
26. Zhou Y, Yu C, Miao X, et al. Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis 2005; 26: 1117-1121
27. Tasci AI, Tugcu V, Ozbek E, Ozbay B, Simsek A, Koksal V,. A single-nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances bladder cancer susceptibility. BJU Int 2008; 101: 503-507
28. Srivastava P, Gangwar R, Kapoor R, Mittal RD,. Bladder cancer risk associated with genotypic polymorphism of the matrix metalloproteinase-1 and 7 in North Indian population. Dis Markers 2010; 29: 37-46
29. Kader AK, Shao L, Dinney CP, et al. Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res 2006; 66: 11644-11648
30. Kader AK, Liu J, Shao L, et al. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin Cancer Res 2007; 13: 2614-2620
31. Srivastava P, Mandhani A, Kapoor R, Mittal RD,. Role of MMP-3 and MMP-9 and their haplotypes in risk of bladder cancer in North Indian cohort. Ann Surg Oncol 2010; 17: 3068-3075
32. Szarvas T, vom Dorp F, Erguen S, Ruebben H,. Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. Nat Rev Urol 2011; 8: 241-254
33. Ozdemir E, Kakehi Y, Okuno H, Yoshida O,. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas. J Urol 1999; 161: 1359-1363
34. Nakopoulou L, Gakiopoulou H, Zervas A, et al. MMP-3 mRNA and MMP-3 and MMP-1 proteins in bladder cancer: a comparison with clinicopathologic features and survival. Appl Immunohistochem Mol Morphol 2001; 9: 130-137
35. Davies B, Waxman J, Wasan H, et al. Levels of matrix metalloproteases in bladder-cancer correlate with tumor grade and invasion. Cancer Res 1993; 53: 5365-5369
36. Donmez G, Sullu Y, Baris S, et al. Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas. Pathol Res Pract 2009; 205: 854-857
37. Grignon DJ, Sakr W, Toth M, et al. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 1996; 56: 1654-1659
38. Wieczorek E, Reszka E, Gromadzinska J, Wasowicz W,. Genetic polymorphism of matrix metalloproteinases in breast cancer. Neoplasma 2012; 59: 237-247
39. Decock J, Paridaens R, Ye S,. Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. Clin Genet 2008; 73: 197-211
40. O'Mara TA, Clements JA, Spurdle AB,. The use of predictive or prognostic genetic biomarkers in endometrial and other hormone-related cancers: justification for extensive candidate gene single nucleotide polymorphism studies of the matrix metalloproteinase family and their inhibitors. Cancer Epidemiol Biomarkers Prev 2009; 18: 2352-2365
41. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ,. Matrix metalloproteinase inhibitors. Invest New Drugs 1997; 15: 61-75
42. Hirata H, Naito K, Yoshihiro S, Matsuyama H, Suehiro Y, Hinoda Y,. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with conventional renal cell carcinoma. Int J Cancer 2003; 106: 372-374
43. Zhu Y, Spitz MR, Lei L, Mills GB, Wu XF,. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res 2001; 61: 7825-7829
44. O-charoenrat P, Leksrisakul P, Sangruchi S,. A functional polymorphism in the matrix metalloproteinase-1 gene promoter is associated with susceptibility and aggressiveness of head and neck cancer. Int J Cancer 2006; 118: 2548-2553
45. Su L, Zhou W, Asomaning K, et al. Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer. Carcinogenesis 2006; 27: 1024-1029
46. Zhou YF, Yu CY, Miao XP, et al. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 2004; 25: 399-404
47. Delgado-Enciso I, Cepeda-Lopez FR, Monrroy-Guizar EA, et al. Matrix metalloproteinase-2 promoter polymorphism is associated with breast cancer in a Mexican population. Gynecol Obstet Invest 2008; 65: 68-72
48. Lei HX, Hemminki K, Altieri A, et al. Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat 2007; 103: 61-69
49. Roehe AV, Frazzon AP, Agnes G, Damin AP, Hartman AA, Graudenz MS,. Detection of polymorphisms in the promoters of matrix metalloproteinases 2 and 9 genes in breast cancer in South Brazil: preliminary results. Breast Cancer Res Treat 2007; 102: 123-124
50. Biondi ML, Turri O, Leviti S, et al. MMP1 and MMP3 polymorphisms in promoter regions and cancer. Clin Chem 2000; 46: 2023-2024
51. Przybylowska K, Zielinska J, Zadrozny M, et al. An association between the matrix metalloproteinase 1 promoter gene polymorphism and lymphnode metastasis in breast cancer. J Exp Clin Cancer Res 2004; 23: 121-125
52. Beeghly-Fadiel A, Cai Q, Lu W, et al. No association between matrix metalloproteinase-1 or matrix metalloproteinase-3 polymorphisms and breast cancer susceptibility: a report from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 2009; 18: 1324-1327
53. Ghilardi G, Biondi ML, Caputo M, et al. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res 2002; 8: 3820-3823
54. Xu E, Lai M, Lu B, Xing X, Huang Q,. No association between the polymorphisms in matrix metalloproteinase-1 and matrix metalloproteinase-3 promoter regions and colorectal cancer in Chinese. Dis Colon Rectum 2006; 49: 1439-1444
55. Hettiaratchi A, Hawkins NJ, McKenzie G, et al. The collagenase-1 (MMP-1) gene promoter polymorphism-1607/2G is associated with favourable prognosis in patients with colorectal cancer. Br J Cancer 2007; 96: 783-792
56. Ghilardi G, Biondi ML, Mangoni J, et al. Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin Cancer Res 2001; 7: 2344-2346
57. Rutter JL, Mitchell TI, Buttice G, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998; 58: 5321-5325
58. Tower GB, Coon CC, Benbow U, Vincenti MP, Brinckerhoff CE,. Erk 1/2 differentially regulates the expression from the 1G/2G single nucleotide polymorphism in the MMP-1 promoter in melanoma cells. Biochim Biophys Acta 2002; 1586: 265-274
59. Zhang B, Ye S, Herrmann SM, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999; 99: 1788-1794
60. Jormsjo S, Ye S, Moritz J, et al. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res 2000; 86: 998-1003
61. Ogata T, Shibamura H, Tromp G, et al. Genetic analysis of polymorphisms in biologically relevant candidate genes in patients with abdominal aortic aneurysms. J Vasc Surg 2005; 41: 1036-1042